Login / Signup

Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies.

Anne Luise Haulund VollesenRaghavendra VasudevaLeah JinLouise LombardElizabeth GrayErin G DotyLaura Yunes-MedinaKraig S KinchenCristina Tassorelli
Published in: Headache (2019)
Patients treated with lasmiditan for a migraine attack reported an earlier onset of efficacy compared with those treated with placebo. Some of the efficacy measures such as pain relief demonstrated improvement as early as the first assessment at 30 minutes after 100- or 200-mg lasmiditan treatment.
Keyphrases
  • double blind
  • placebo controlled
  • clinical trial
  • phase ii
  • squamous cell carcinoma
  • study protocol
  • liver failure
  • combination therapy
  • radiation therapy
  • pain management
  • open label
  • spinal cord injury
  • replacement therapy